sCD163 in PBC Patients - Assessment of Treatment Response
Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA
University of Aarhus
40 participants
Sep 1, 2016
OBSERVATIONAL
Conditions
Summary
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
Eligibility
Inclusion Criteria2
- Newly diagnosed with Primary biliary cholangitis
- No treatment with UDCA
Exclusion Criteria5
- Patient under 18 years
- Expected lifetime under 6 months
- Expected liver transplantation within 6 months
- Liver cancer
- Cirrhosis from other causes
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02931513